AGTR1 and stroke disorder: Clinical and basic studies have revealed the ability of AT1R blockers to reduce the incidence and protect tissue injury from stroke independent of the blood pressure-lowering effect [25-29], while animal studies demonstrate attenuated inflammatory and injury responses in post-ischemic brain following pharmacologic blockade or genetic deletion of AT1R [8].